Alessandro Lagana

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9894425/publications.pdf

Version: 2024-02-01

43
papers

1,118
citations

516710

16
h-index

414414

32
g-index

47
all docs

47
docs citations

47
times ranked

2113
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of a first-in-class EZH2 selective degrader. Nature Chemical Biology, 2020, 16, 214-222.	8.0	148
2	Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nature Medicine, 2021, 27, 2099-2103.	30.7	92
3	A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy. Cancer Discovery, 2021, 11, 599-613.	9.4	90
4	A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies. Oncotarget, 2015, 6, 20829-20839.	1.8	89
5	MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8650-8655.	7.1	86
6	Noncoding RNA: Current Deep Sequencing Data Analysis Approaches and Challenges. Human Mutation, 2016, 37, 1283-1298.	2.5	74
7	Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma. Clinical Cancer Research, 2020, 26, 450-464.	7.0	62
8	miRandola 2017: a curated knowledge base of non-invasive biomarkers. Nucleic Acids Research, 2018, 46, D354-D359.	14.5	61
9	PDGFR-modulated miR-23b cluster and miR-125a-5p suppress lung tumorigenesis by targeting multiple components of KRAS and NF-kB pathways. Scientific Reports, 2017, 7, 15441.	3.3	49
10	Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications. Science Advances, 2021, 7, eabg9551.	10.3	49
11	microRNA editing in seed region aligns with cellular changes in hypoxic conditions. Nucleic Acids Research, 2016, 44, 6298-6308.	14.5	41
12	A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. Blood Advances, 2017, 1, 1575-1583.	5.2	39
13	KRAS induces lung tumorigenesis through microRNAs modulation. Cell Death and Disease, 2018, 9, 219.	6.3	39
14	Quaking and<i>miR-155</i>interactions in inflammation and leukemogenesis. Oncotarget, 2015, 6, 24599-24610.	1.8	37
15	A Network Analysis of Multiple Myeloma Related Gene Signatures. Cancers, 2019, 11, 1452.	3.7	23
16	Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach. JCO Precision Oncology, 2018, 2018, 1-17.	3.0	20
17	MiREDiBase, a manually curated database of validated and putative editing events in microRNAs. Scientific Data, 2021, 8, 199.	5.3	18
18	Computational Prediction of microRNA Targets. Advances in Experimental Medicine and Biology, 2015, 887, 231-252.	1.6	14

#	ARTICLE	IF	CITATIONS
19	A Phase II Study of Panobinostat with Lenalidomide and Weekly Dexamethasone in Myeloma. Blood, 2015, 126, 4226-4226.	1.4	14
20	MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21Cip1. Oncotarget, 2020, 11, 727-739.	1.8	12
21	A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia and Lymphoma, 2020, 61, 2208-2215.	1.3	7
22	A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma. JCO Precision Oncology, 2022, , .	3.0	7
23	SOX11 Inhibitors Are Cytotoxic in Mantle Cell Lymphoma. Clinical Cancer Research, 2021, 27, 4652-4663.	7.0	6
24	Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T. Blood, 2021, 138, 2704-2704.	1.4	6
25	Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e975-e984.	0.4	5
26	Single-Cell Profiling Reveals Contribution of Tumor Extrinsic and Intrinsic Factors to BCMA-Targeted CAR-T Cell Efficacy in Multiple Myeloma. Blood, 2021, 138, 326-326.	1.4	5
27	Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Iberdomide-Treated Myeloma Patients. Blood, 2021, 138, 730-730.	1.4	4
28	MAGE-a Mediate Resistance to Chemotherapy in Multiple Myeloma through Regulation of Bcl-2 Proteins. Blood, 2016, 128, 3277-3277.	1.4	3
29	A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma. Blood, 2019, 134, 3101-3101.	1.4	2
30	(Distinct) origins of IgM myeloma. Blood, 2021, 138, 1914-1915.	1.4	2
31	Pathogenic Germline Variants in Multiple Myeloma. Blood, 2021, 138, 399-399.	1.4	2
32	Editorial: Bioinformatics of Non-Coding RNAs with Applications to Biomedicine: Recent Advances and Open Challenges. Frontiers in Bioengineering and Biotechnology, 2015, 3, 156.	4.1	1
33	MicroRNA profiling of blastic plasmacytoid dendritic cell neoplasm and myeloid sarcoma. Hematological Oncology, 2020, 38, 831-833.	1.7	1
34	Integrative Network Analysis of Newly Diagnosed Multiple Myeloma Identifies a Novel RNA-Seq Based High Riskgene Signature. Blood, 2016, 128, 3285-3285.	1.4	1
35	Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature. Blood, 2021, 138, 457-457.	1.4	1
36	Aberrant Cell Cycle Programming Confers Rapid Lethality in the EuSOX11+ CCND1 MCL Mouse Model. Blood, 2020, 136, 6-7.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Continuous genomic monitoring of multiple myeloma patients to identify patients of high risk for poor prognosis.. Journal of Clinical Oncology, 2021, 39, e20035-e20035.	1.6	0
38	Towards a Network-Based Molecular Taxonomy of Newly Diagnosed Multiple Myeloma. Blood, 2015, 126, 840-840.	1.4	0
39	Aberrant a-to-I RNA Editing and Prognostic Impact of Adar in Multiple Myeloma Patients with 1q Amplification. Blood, 2016, 128, 357-357.	1.4	0
40	Mutation Burden in Multiple Myeloma Is Captured By Gene Expression Profiles. Blood, 2016, 128, 4450-4450.	1.4	0
41	MAGE-A3 Promotes Chemotherapy Resistance and Proliferation in Multiple Myeloma through Regulation of BIM and p21Cip1. Blood, 2018, 132, 4464-4464.	1.4	0
42	Development of a Neoantigen Prediction Tool for Patient Stratification in Immuno-Oncology Trials. Blood, 2018, 132, 2215-2215.	1.4	0
43	Title: Genomic and Systemic Metabolism Differences Associated with Racial Disparities in Multiple Myeloma. Blood, 2021, 138, 1601-1601.	1.4	0